| Funding Opportunity Full Description | Idea Award Funding Opportunity Number: HT942526LRPIA
Basic Information About the Funding Opportunity Summary: This funding mechanism supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement relevant to lupus. The emphasis is on innovation. Research must address at least one of the fiscal year 2026 (FY26) Lupus Research Program (LRP) Idea Award (IA) focus areas. This funding mechanism does not allow clinical trials. Distinctive Features: • Early-career investigators are eligible to serve as Principal Investigators (PIs) on applications to the FY26 LRP Idea Award (see Section 2. Eligibility Information). • Preliminary data are permitted but not required. • Applications should describe future directions of the work. • An individual may be named as PI on only one application per LRP award mechanism (IA, Impact Award, Transformative Vision Development Award, Transformative Vision Award), for a maximum of four applications to the FY26 LRP. Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $1.5M to fund approximately five Idea Award applications with total cost caps of $300,000 per award. The maximum period of performance is 2 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.
Impact Award Funding Opportunity Number: HT942526LRPIPA
Basic Information About the Funding Opportunity Summary: This funding mechanism supports high-risk/high-reward research that has the potential to make a major impact in lupus research and/or lupus disease. The emphasis is on impact. Research must address at least one of the fiscal year 2026 (FY26) Lupus Research Program (LRP) Impact Award (IPA) focus areas. This funding mechanism does not allow clinical trials. Distinctive Features: The FY26 LRP IPA encourages, but does not require, preliminary data. An individual may be named as Principal Investigator (PI) on only one application per LRP award mechanism (Idea Award, IPA, Transformative Vision Development Award, Transformative Vision Award), for a maximum of four applications to the FY26 LRP. Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $5M to fund approximately five Impact Award applications with total cost caps of $1M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.
Transformative Vision Award Funding Opportunity Number: HT942526LRPTVA
Basic Information About the Funding Opportunity Summary: This funding mechanism supports interventional research at the individual and/or health care system level which will result in near-term impact on the health-related quality of life of individuals living with lupus. The emphasis is on near-term impact on quality of life. Research must address at least one of the fiscal year 2026 (FY26) Lupus Research Program (LRP) Transformative Vision Award (TVA) focus areas. This mechanism allows for clinical trials but does not allow animal studies.
Distinctive Features:
• Applications must include preliminary data.
• Applications must include at least one lupus consumer advocate as a member of the research team.
• This funding mechanism allows for up to three Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application(s) is rejected or administratively withdrawn.
• An individual may be named as PI on only one application per LRP award mechanism (Idea Award, Impact Award, Transformative Vision Development Award, TVA), for a maximum of four applications to the FY26 LRP.
Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $2M to fund approximately one Transformative Vision Award application with a total cost cap of $2M. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.
Transformative Vision Development Award Funding Opportunity Number: HT942526LRPTVDA
Basic Information About the Funding Opportunity Summary: This funding mechanism supports planning and development activities and pilot studies that will generate preliminary data and demonstrate feasibility for achieving the aims of a future interventional study. Successful studies may be submitted to a future Lupus Research Program (LRP) Transformative Vision Award (TVA), or equivalent, for funding consideration (See Funding Opportunity Number HT942526LRPTVA for additional information). Research must address at least one of the fiscal year 2026 (FY26) LRP Transformative Vision Development Award (TVDA) focus areas. This funding mechanism allows for phase 0/1 clinical trials, if appropriate. The mechanism does not allow for phase 2/3 clinical trials or animal studies. Distinctive Features: • Preliminary data are permitted but not required. • Applications must include at least one lupus consumer advocate as a member of the research team. • An individual may be named as Principal Investigator (PI) on only one application per LRP award mechanism (Idea Award, Impact Award, TVDA, TVA), for a maximum of four applications to the FY26 LRP. Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $500,000 to fund approximately two Transformative Vision Development Award applications with total cost caps of $250,000 per award. The maximum period of performance is 2 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.
|
|---|
